Systemic VEGF-A Neutralization Ameliorates Diet-Induced Metabolic Dysfunction
Lindsay E Wu, Christopher C Meoli, Salvatore P Mangiafico, Daniel J Fazakerley, Victoria C Cogger, Mashani Mohamad, Himani Pant, Myung-Jin Kang, Elizabeth Powter, James G Burchfield, Chrysovalantou E Xirouchaki, A Stefanie Mikolaizak, Jacqueline Stoeckli, Ganesh Kolumam, Nicholas van Bruggen, Jennifer R Gamble, David G Le Couteur, Gregory J Cooney, Sofianos Andrikopoulos, David E James
Diabetes | AMER DIABETES ASSOC | Published : 2014
The vascular endothelial growth factor (VEGF) family of cytokines are important regulators of angiogenesis that have emerged as important targets for the treatment of obesity. While serum VEGF levels rise during obesity, recent studies using genetic models provide conflicting evidence as to whether VEGF prevents or accelerates metabolic dysfunction during obesity. In the current study, we sought to identify the effects of VEGF-A neutralization on parameters of glucose metabolism and insulin action in a dietary mouse model of obesity. Within only 72 h of administration of the VEGF-A-neutralizing monoclonal antibody B.20-4.1, we observed almost complete reversal of high-fat diet-induced insuli..View full abstract
Funding. L.E.W. is supported by an Early Career Fellowship from Cancer Institute New South Wales, Australia. This work was supported by a program grant from the NHMRC of Australia. D.E.J. is a senior principal research fellow of the NHMRC.